We are live on
!
Find out more
SOCM
SR One Capital Management Portfolio holdings
AUM
$915M
1-Year Est. Return
209.71%
This Fund
S&P 500
This Quarter
Est. Return
+18.03%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$177M
AUM Growth
–
Cap. Flow
+$160M
Cap. Flow
% of AUM
90.4%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
2
New
2
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Design Therapeutics
DSGN
|
+$96.6M |
| 2 |
EFTR
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
|
+$63.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
PTC
SC
SI
GIG
SAA
GC
KCM
FFL
SR One Capital Management's Q4 2021 Portfolio in Review
Q4 2021 is the first quarter with a 13F filing on record for SR One Capital Management, which disclosed 2 positions worth $177M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Design Therapeutics: 5,626,476 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- SR One Capital Management's largest Q4 2021 buy was Design Therapeutics: 5,626,476 shares worth $120M.
- SR One Capital Management's ten largest holdings make up 100% of its $177M portfolio in Q4 2021.
- SR One Capital Management disclosed 2 positions in Q4 2021, its first 13F filing on record.
Based on SR One Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.